These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 36992304)

  • 1. Biomimetic Nanotechnology for SARS-CoV-2 Treatment.
    Li S; Liu X; Liu G; Liu C
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotechnology-based strategies against SARS-CoV-2 variants.
    Huang X; Kon E; Han X; Zhang X; Kong N; Mitchell MJ; Peer D; Tao W
    Nat Nanotechnol; 2022 Oct; 17(10):1027-1037. PubMed ID: 35982317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnologies for the Diagnosis and Treatment of SARS-CoV-2 and Its Variants.
    Park E; Choi SY; Kim J; Hildebrandt N; Lee JS; Nam JM
    Small Methods; 2023 Jul; 7(7):e2300034. PubMed ID: 37189215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies.
    Hasanzadeh A; Alamdaran M; Ahmadi S; Nourizadeh H; Bagherzadeh MA; Mofazzal Jahromi MA; Simon P; Karimi M; Hamblin MR
    J Control Release; 2021 Aug; 336():354-374. PubMed ID: 34175366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomimetic Virus-Like Particles as Severe Acute Respiratory Syndrome Coronavirus 2 Diagnostic Tools.
    Chan SK; Du P; Ignacio C; Mehta S; Newton IG; Steinmetz NF
    ACS Nano; 2021 Jan; 15(1):1259-1272. PubMed ID: 33237727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine approaches against SARS-CoV-2 and variants.
    Zhang H; Liu Y; Liu Z
    J Control Release; 2024 Jan; 365():101-111. PubMed ID: 37951476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic.
    Weiss C; Carriere M; Fusco L; Capua I; Regla-Nava JA; Pasquali M; Scott JA; Vitale F; Unal MA; Mattevi C; Bedognetti D; Merkoçi A; Tasciotti E; Yilmazer A; Gogotsi Y; Stellacci F; Delogu LG
    ACS Nano; 2020 Jun; 14(6):6383-6406. PubMed ID: 32519842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article.
    Saied AA; Metwally AA; Alobo M; Shah J; Sharun K; Dhama K
    Int J Surg; 2022 Feb; 98():106233. PubMed ID: 35065260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding and combating COVID-19 using the biology and chemistry of SARS-CoV-2.
    Khan MM; Goh YW; Ahmad N; Siddique MM
    Bioprocess Biosyst Eng; 2022 Nov; 45(11):1753-1769. PubMed ID: 36125525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19.
    Li Z; Wang Z; Dinh PC; Zhu D; Popowski KD; Lutz H; Hu S; Lewis MG; Cook A; Andersen H; Greenhouse J; Pessaint L; Lobo LJ; Cheng K
    Nat Nanotechnol; 2021 Aug; 16(8):942-951. PubMed ID: 34140674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotechnology-Based Strategies for the Management of COVID-19: Recent Developments and Challenges.
    Singh R; Behera M; Kumari N; Kumar S; Rajput VD; Minkina TM; Adnan M; Siddiqui AJ; Kumar N
    Curr Pharm Des; 2021; 27(41):4197-4211. PubMed ID: 34459371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Patents and Advances on Nanotechnologies against Coronavirus.
    Abedini-Nassab R; Mahdaviyan N
    Recent Pat Nanotechnol; 2021; 15(4):322-330. PubMed ID: 33172382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A SARS-CoV-2-Related Virus from Malayan Pangolin Causes Lung Infection without Severe Disease in Human ACE2-Transgenic Mice.
    Liu MQ; Lin HF; Li J; Chen Y; Luo Y; Zhang W; Hu B; Tian FJ; Hu YJ; Liu YJ; Jiang RD; Gong QC; Li A; Guo ZS; Li B; Yang XL; Tong YG; Shi ZL
    J Virol; 2023 Feb; 97(2):e0171922. PubMed ID: 36688655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnology and COVID-19 Convergence: Toward New Planetary Health Interventions Against the Pandemic.
    Sahoo P; Dey J; Mahapatra SR; Ghosh A; Jaiswal A; Padhi S; Prabhuswamimath SC; Misra N; Suar M
    OMICS; 2022 Sep; 26(9):473-488. PubMed ID: 36040392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Pathogenesis of SARS-CoV-2 Variants of Concern in Human ACE2-Expressing Mice.
    Natekar JP; Pathak H; Stone S; Kumari P; Sharma S; Auroni TT; Arora K; Rothan HA; Kumar M
    Viruses; 2022 May; 14(6):. PubMed ID: 35746611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19.
    Kumar A; Parashar R; Kumar S; Faiq MA; Kumari C; Kulandhasamy M; Narayan RK; Jha RK; Singh HN; Prasoon P; Pandey SN; Kant K
    J Med Virol; 2022 Apr; 94(4):1300-1314. PubMed ID: 34811761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.